3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
17
INDUSTRY
5
Study Type
Observational
3
Interventional
2
Sponsor
Cancer Type
Classical hematology
5
Conditions
Venous Thromboembolism
5
Neoplasms
4
Pulmonary Embolism
3
Venous Thrombosis
2
Thrombosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma
1
Embolism
1
Interventions
apixaban
5
Rivaroxaban
5
Dalteparin
4
Enoxaparin
3
edoxaban
2
abelacimab
2
Tinzaparin
2
MAA868
2
Heparin, Low-Molecular-Weight
2
Dabigatran
2
isoquercitrin
1
calcium heparin
1
betrixaban
1
bemiparin
1
Warfarin
1
Heparin
1
Gemcitabine
1
Fondaparinux
1
AVE 5026
1
ALT-836
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
INDUSTRY
×
Venous Thromboembolism
×
apixaban
×
Clear all
NCT07493304
2026-05-29
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,600 enrolled
NCT04618913
2026-05-26
VICTORIE
Pfizer
Active not recruiting
1 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled
NCT05461807
2022-10-26
H2H-OSCAR-US
Bayer
Completed
2,437 enrolled
NCT03965741
2021-11-30
PRACTISE
Bayer
Completed
97,765 enrolled